ERG and prostate carcinoma: A previous report on mTOR phosphorylation in prostate cancer identified a small subpopulation of p-mTOR negative patients who may benefit from mTOR inhibition by integrating mTOR phosphorylation, ERG fusion and PTEN mutation status [18].